Collegium Medicum w Bydgoszczy

Quick facts

Marketed products

• Crushed ticagrelor followed by morphine · Cardiovascular
  Crushed ticagrelor inhibits platelet aggregation via P2Y12 receptor antagonism, followed by morphine administration for pain relief and anxiolysis.
• Crushed ticagrelor, morphine,metoclopramide · Cardiovascular / Acute Coronary Syndrome with pain management
  This combination uses ticagrelor to inhibit platelet aggregation, morphine for pain relief and anxiolysis, and metoclopramide to enhance gastric motility and reduce nausea.
• Crushed ticagrelor, morphine,naloxone · Cardiovascular / Pain Management
  This combination uses ticagrelor to inhibit platelet aggregation, morphine for pain relief and anxiolysis, and naloxone as an opioid antagonist to reduce morphine-related adverse effects.
• Integral ticagrelor · Cardiovascular
  Ticagrelor is a P2Y12 platelet receptor antagonist that inhibits platelet aggregation and reduces thrombotic events.
• Pulverized ticagrelor orally
• Pulverized ticagrelor sublingually
• Rosuvastatin and Ezetimibe morning or evening administration
• Ticagrelor followed with Methoxyflurane · Cardiovascular; Pain Management
  Ticagrelor inhibits platelet aggregation via P2Y12 receptor antagonism, while methoxyflurane provides rapid analgesia through NMDA receptor modulation and other mechanisms.
• Ticagrelor followed with Morphine · Cardiovascular
  Ticagrelor inhibits platelet aggregation via P2Y12 receptor antagonism, while morphine provides opioid analgesia; together they are used in acute coronary syndrome to prevent thrombotic events and manage pain.

Phase 2 pipeline

• Flozin · Other

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Collegium Medicum w Bydgoszczy portfolio CI brief
• Collegium Medicum w Bydgoszczy pipeline updates RSS